| Filed On | Filing |
|---|---|
| 22 Sep 2026 |
8-K: Other Events
In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exe... |
| 26 Aug 2026 |
8-K: Other Events
On August 26, 2026, LeonaBio, Inc. (the “Company”) announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor, as a t... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 22, 2026, LeonaBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company had 9,393,514 shares of common stock, par value $0.0001 per share (the “common stock”), outstanding on May ... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations |
| 19 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
to attract and retain the best available personnel for positions of substantial responsibility, |
| 09 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
The registered office of LeonaBio, Inc. (the “Company”) shall be fixed in the Company’s certificate of incorporation, as the same may be amended from time to time. |
| 18 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
You should carefully consider the following risk factors, in addition to the other information contained in this Current Report on Form 8-K, or the Form 8-K, the Company’s Annual Report on Form 10-K filed on February 27, 2025 and the Com... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Continuing to explore strategic alternatives focusing on maximizing stockholder value |
| 03 Oct 2025 |
8-K: Other Events
As previously reported, on October 16, 2024, Athira Pharma, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid pric... |
| 11 Sep 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Athira Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development |
| 02 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 29, 2025, Athira Pharma, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The Company had 39,042,445 shares of common stock outstanding on April 4, 2025, the record date for the Annual Meet... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 |
| 16 Apr 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On April 15, 2025, Athira Pharma, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) approving the transfer of the listing of the Company’s common stock, par value $0.0... |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 |
| 18 Oct 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
On October 16, 2024, Athira Pharma, Inc. (the “Company”) received a notification letter (the “Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on t... |
| 07 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
*Certain portions of this exhibit have been omitted because they are not material and is the type of information that the company treats as private or confidential. |
Loading...